SAB Biotherapeutics Q2 2026, Cash Balance Of $208.0M, Providing Runway Through 2028
Share
Why It Matters
SAB Biotherapeutics has $208 million in cash, which means they can keep running their company and paying their team until 2028 without needing to raise more money right now. When a company has a clear money runway, it tells you they have time to work on their ideas without being in a rush.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.